CLAIMS

~~We claim:~~

1. A method of decreasing body weight in a subject, comprising administering a composition comprising a fusion protein comprising SEQ ID NO: 92, and at least one pharmaceutically acceptable carrier or diluent, wherein said fusion protein is administered at a dose in the range of 0.8 mg to 90 mg, and wherein the subject's weight is 80 kg or more~~.~~

~~2. The method of claim 1~~, wherein the subject is overweight.

~~3. The method of claim 2, wherein the subject has a BMI of 25 kg/m2 or more.~~

~~4. The method of claim 3, wherein the subject has the BMI in the range of 25 kg/m2 to 29.9 kg/m2.~~

~~5. The method of claim 1, wherein the fusion protein is administered at a dose selected from the group consisting of: 0.8 mg, 2.5 mg, 7.5 mg, 15 mg, 30 mg, 60 mg, and 90 mg.~~

~~6. The method of claim 5, wherein fusion protein is administered at a dose of 0.8 mg.~~

~~7. The method of claim 5, wherein fusion protein is administered at a dose of 2.5 mg.~~

~~8. The method of claim 5, wherein fusion protein is administered at a dose of 7.5 mg.~~

~~9. The method of claim 5, wherein fusion protein is administered at a dose of 15 mg.~~

~~10. The method of claim 5, wherein fusion protein is administered at a dose of 30 mg.~~

~~11. The method of claim 5, wherein fusion protein is administered at a dose of 60 mg.~~

~~12. The method of claim 5, wherein fusion protein is administered at a dose of 90 mg.~~

~~13. The method of claim 1, wherein the fusion protein is administered via subcutaneous injection.~~

~~14. The method of claim 1 wherein the composition is administered once weekly to the subject.~~

15. A method of decreasing food intake in a subject, comprising administering a composition comprising a fusion protein comprising SEQ ID NO: 92, and at least one pharmaceutically acceptable carrier or diluent, wherein said fusion protein is administered at a dose in the range of 0.8 mg to 90 mg, and wherein the subject weight is 80 kg or more.

16. The method of claim 15, wherein the subject is overweight.

17. The method of claim 16, wherein the subject has a BMI of 25 kg/m2 or more.

18. The method of claim 17, wherein the subject has the BMI in the range of 25 kg/m2 to 29.9 kg/m2.

19. The method of claim 15, wherein the fusion protein is administered at a dose selected from the group consisting of: 0.8 mg, 2.5 mg, 7.5 mg, 15 mg, 30 mg, 60 mg, and 90 mg.

20. The method of claim 19, wherein fusion protein is administered at a dose of 0.8 mg.

21. The method of claim 19, wherein fusion protein is administered at a dose of 2.5 mg.

22. The method of claim 19, wherein fusion protein is administered at a dose of 7.5 mg.

23. The method of claim 19, wherein fusion protein is administered at a dose of 15 mg.

24. The method of claim 19, wherein fusion protein is administered at a dose of 30 mg.

25. The method of claim 19, wherein fusion protein is administered at a dose of 60 mg.

26. The method of claim 19, wherein fusion protein is administered at a dose of 90 mg.

27. The method of claim 15, wherein the fusion protein is administered via subcutaneous injection.

28. The method of claim 15 wherein the composition is administered once weekly to the subject.

29. A method of decreasing body weight in a subject, comprising administering a composition comprising a fusion protein comprising SEQ ID NO: 92, and at least one

~~pharmaceutically acceptable carrier or diluent, wherein said composition is administered at a dose in a range of 0.01 mg/kg to 1.08 mg/kg.~~

~~30. The method of claim 29, wherein said composition is administered at a dose selected from the group consisting of: 0.01 mg/kg, 0.03 mg/kg, 0.09 mg/kg, 0.18 mg/kg, 0.36 mg/kg, 0.72 mg/kg, and 1.08 mg/kg.~~

~~31. The method of claim 29, wherein said composition is administered at a dose of 0.01 mg/kg.~~

~~32. The method of claim 29, wherein said composition is administered at a dose of 0.03 mg/kg.~~

~~33. The method of claim 29, wherein said composition is administered at a dose of 0.09 mg/kg.~~

~~34. The method of claim 29, wherein said composition is administered at a dose of 0.18 mg/kg.~~

~~35. The method of claim 29, wherein said composition is administered at a dose of 0.36 mg/kg.~~

~~36. The method of claim 29, wherein said composition is administered at a dose of 0.72 mg/kg.~~

~~37. The method of claim 29, wherein said composition is administered at a dose of 1.08 mg/kg.~~

~~38. The method of claim 29, wherein the fusion protein is administered via subcutaneous injection.~~

~~39. The method of claim 29 wherein the composition is administered once weekly to the subject.~~

~~40. A method of decreasing food intake in a subject, comprising administering a composition comprising a fusion protein comprising SEQ ID NO: 92, and at least one pharmaceutically acceptable carrier or diluent, wherein said composition is administered at a dose in a range of 0.01 mg/kg to 1.08 mg/kg.~~

~~41. The method of claim 40, wherein said composition is administered at a dose selected from the group consisting of: 0.01 mg/kg, 0.03 mg/kg, 0.09 mg/kg, 0.18 mg/kg, 0.36 mg/kg, 0.72 mg/kg, and 1.08 mg/kg.~~

~~42. The method of claim 41, wherein said composition is administered at a dose of 0.01 mg/kg.~~

~~43. The method of claim 41, wherein said composition is administered at a dose of 0.03 mg/kg.~~

~~44. The method of claim 41, wherein said composition is administered at a dose of 0.09 mg/kg.~~

~~45. The method of claim 41, wherein said composition is administered at a dose of 0.18 mg/kg.~~

~~46. The method of claim 41, wherein said composition is administered at a dose of 0.36 mg/kg.~~

~~47. The method of claim 41, wherein said composition is administered at a dose of 0.72 mg/kg.~~

~~48. The method of claim 41, wherein said composition is administered at a dose of 1.08 mg/kg.~~

~~49. The method of claim 41, wherein the fusion protein is administered via subcutaneous injection.~~

~~50. The method of claim 41, wherein the composition is administered once weekly to the subject.~~